Quarterly report · Q1
4564.TEDINET S100ROVK
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥148m | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥386m | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥386m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | −¥307m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥397m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥314m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥277m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥400m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.3bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥2.0bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥346m | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥930m | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥913m | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-1.99 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.44 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥122,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥122,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥102m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥148m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥148m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥51m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥509,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥387,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥122,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥233m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥148m |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥148m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥122,000 |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | −¥284m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥101m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥215m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | −¥206m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 300
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment loss el | Prior1YTDDuration | 751000 | JPY |
| Impairment loss el | CurrentYTDDuration | 2627000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 751000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 2627000 | JPY |
| Income before income taxes | Prior1YTDDuration | -277089000 | JPY |
| Income before income taxes | CurrentYTDDuration | -399873000 | JPY |
| Income taxes current | Prior1YTDDuration | 724000 | JPY |
| Income taxes current | CurrentYTDDuration | 612000 | JPY |
| Income taxes deferred | Prior1YTDDuration | -14000 | JPY |
| Income taxes deferred | CurrentYTDDuration | － | JPY |
| Income taxes | Prior1YTDDuration | 710000 | JPY |
| Income taxes | CurrentYTDDuration | 612000 | JPY |
| Profit loss | Prior1YTDDuration | -277799000 | JPY |
| Profit loss | CurrentYTDDuration | -400486000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | -277799000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | -400486000 | JPY |
| Profit loss | Prior1YTDDuration | -277799000 | JPY |
| Profit loss | CurrentYTDDuration | -400486000 | JPY |
| Comprehensive income | Prior1YTDDuration | -277799000 | JPY |
| Comprehensive income | CurrentYTDDuration | -400486000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | -277799000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | -400486000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 5610000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 380093000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 385703000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 385703000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 55000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 55000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -55000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 5665000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 380093000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 385759000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -55000 | JPY |
| Net sales | Prior1YTDDuration | 385703000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -215473000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 9271000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -206202000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -101150000 | JPY |
| Operating income | Prior1YTDDuration | -307352000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 387000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 147749000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 148137000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 148137000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 122000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 122000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |